Negative Trials
15
-
Upload
wesley-wallace -
Category
Documents
-
view
27 -
download
0
description
Negative Trials. TRILOGY ACS No significant difference in ischemic outcomes despite greater P2Y 12 receptor inhibition with prasugrel than with clopidogrel. ISIS-2, GUSTO: Exclusion Criteria. Today’s Trial Design Challenges. NIH Health Care Systems Research Collaboratory. - PowerPoint PPT Presentation
Transcript of Negative Trials
TRILOGY ACSNo significant difference in ischemic outcomes despite greater P2Y12 receptor inhibition with prasugrel than with clopidogrel